A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 29, 2013

Primary Completion Date

June 1, 2016

Study Completion Date

July 11, 2016

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG

OPB-111077

Trial Locations (1)

Seoul & Gyeonggi-Do